Pulmonary toxicity of antineoplastic agents: Anaesthetic and postoperative implications

Pulmonary toxicity of antineoplastic agents: anaesthetic and postoperative implications.

Agents commonly used in the treatment of neoplastic diseases may impair pulmonary function, and a wide spectrum of agents are currently implicated as toxic to the pulmonary system. Agents most commonly implicated are bleomycin, carmustine, busulfan, methotrexate, and thoracic radiotherapy. Less commonly implicated agents include mitomycin, procarbazine, melphalan, chlorambucil, and cyclophospha...

Toxicity of inhalation anaesthetic agents.

Although hundreds of compounds on the chemist's shelf are known to produce anaesthesia, relatively few are used clinically. The requirements for a clinically useful anaesthetic agent are necessarily stringent and include: a wide margin of safety, total reversibility of anaesthetic effect and an absence of long-term toxicity. In addition, a successful inhalation anaesthetic agent must combine th...

Postoperative pulmonary complications using dry and humidified anaesthetic gases.

A controlled double-blind study was undertaken to ascertain whether hnmidification of the anaesthetic gas altered the pulmonary complication rate as compared with dry gas, when administered in a non-rebreathing system to adult patients undergoing abdominal and/or transthoracic operations. Eighty-four patients, anaesthetized on an average for 5 hours, were studied. Sequential analysis showed tha...

Antineoplastic Agents for Solid Tumors Pulmonary Complications of Novel

2008;133;528-538 Chest Bobbak Vahid and Paul E. Marik Antineoplastic Agents for Solid Tumors Pulmonary Complications of Novel http://chestjournal.org/cgi/content/abstract/133/2/528 and services can be found online on the World Wide Web at: The online version of this article, along with updated information ). ISSN: 0012-3692. http://www.chestjournal.org/misc/reprints.shtml ( of the copyright hol...

Antineoplastic Agents